The 2026 Obesity Drug Pipeline
Reviewed 2026-07-25 · 9 min read
The race to treat obesity has moved far beyond a single hormone. The drugs arriving now combine two, three, or four appetite and metabolism pathways at once, and the ones producing the biggest results all share that multi-receptor design. Here is every major compound in the pipeline, what it targets, and where it stands, each linked to its full evidence profile.
The pipeline at a glance
| Compound | Mechanism | Stage | Peak result |
|---|---|---|---|
| SemaglutideNovo Nordisk | GLP-1 | Approved | ~15% |
| TirzepatideEli Lilly | GLP-1 / GIP | Approved | ~21% |
| RetatrutideEli Lilly | GLP-1 / GIP / glucagon (triple) | Phase 3 | ~24% |
| CagriSemaNovo Nordisk | GLP-1 + amylin | Filed with FDA | ~23% |
| MariTideAmgen | GLP-1 agonist / GIP antagonist | Phase 3 | ~20% |
| VK2735Viking | GLP-1 / GIP | Phase 3 | ~15% (13 wk) |
| AmycretinNovo Nordisk | GLP-1 + amylin (one molecule) | Phase 2 → 3 | ~14.5% (36 wk) |
| SurvodutideBoehringer / Zealand | GLP-1 / glucagon | Phase 3 | MASH + obesity |
| MazdutideInnovent / Lilly | GLP-1 / glucagon | Approved (China) | Substantial |
| PemvidutideAltimmune | GLP-1 / glucagon | Phase 2 | Lean-mass sparing |
| EfocipegtrutideHanmi | GLP-1 / GIP / glucagon (triple) | Phase 2 | MASH focus |
| PetrelintideRoche / Zealand | Amylin (monotherapy) | Phase 2 → 3 | ~10.7% (42 wk) |
| OrforglipronEli Lilly | Oral GLP-1 (small molecule) | Phase 3 | Oral |
| DanuglipronPfizer | Oral GLP-1 (small molecule) | Discontinued | Halted |
| EcnoglutideSciwind | Long-acting GLP-1 | Phase 3 (China) | Extended dosing |
| BimagrumabEli Lilly | Activin receptor antibody | Phase 2 | Builds muscle |
Weight-loss figures are the peak values reported in each drug's own trials and are not head-to-head. Trial lengths differ (some 13 weeks, others 68 weeks), so the percentages are not directly comparable. Figures reflect published results as of the review date.
Triple agonists: the heavy hitters
The most powerful results come from drugs that hit three pathways at once: GLP-1 for appetite and insulin, GIP for complementary metabolic effects, and glucagon for energy expenditure and liver fat. Retatrutide is the front-runner, with the largest pharmacological weight loss reported to date. Efocipegtrutide uses the same triple design with a focus on metabolic liver disease.
GLP-1 and GIP: activate, or block?
The approved Tirzepatide established dual GLP-1/GIP agonism. VK2735follows the same approach in both injectable and oral forms. Then there is the twist: Amgen's MariTide activates GLP-1 but deliberately blocks GIP, and still produces about 20% weight loss on once-monthly dosing. Whether activating or blocking GIP is better is one of the most interesting open questions in the field.
GLP-1 and glucagon: burning more, not just eating less
Adding glucagon activity increases energy expenditure and reduces liver fat, which makes these drugs especially interesting for metabolic liver disease alongside obesity. Survodutide, Mazdutide (already approved in China), and Pemvidutide all take this route, with pemvidutide emphasizing preservation of lean muscle.
Amylin: the other appetite pathway
Amylin is a separate satiety hormone, and amylin drugs may be better tolerated than GLP-1 agonists. Cagrilintide is the long-acting amylin analogue at the center of CagriSema (paired with semaglutide for about 23% weight loss). Amycretin folds GLP-1 and amylin into a single molecule, and Petrelintide is being developed as an amylin-only option. The original short-acting amylin drug, Pramlintide, has been approved for years.
The oral race, and muscle preservation
A pill would change access dramatically. Orforglipronis an oral small-molecule GLP-1 agonist in Phase 3, while Pfizer's Danuglipron was discontinued over tolerability and a liver signal. Ecnoglutide pushes toward less frequent dosing. And because GLP-1 weight loss costs some muscle, Bimagrumab is being studied to build muscle while fat comes off.
Frequently asked questions
What is the most effective obesity drug in the 2026 pipeline?
By peak weight loss reported in trials, the triple agonist retatrutide (~24%) and the combination CagriSema (~23%) lead, with Amgen's MariTide around 20% on monthly dosing. All three target multiple receptors, which is the defining trend of the new pipeline.
Why are the newest drugs targeting multiple receptors?
Single-pathway GLP-1 drugs plateau in effect. Adding GIP, glucagon, or amylin activity engages complementary appetite and energy-expenditure pathways, and in trials the extra receptors have produced real additional weight loss rather than just theoretical benefit.
Will there be a weight-loss pill instead of an injection?
Several oral options are in development. Orforglipron is an oral small-molecule GLP-1 agonist in Phase 3, and an oral form of VK2735 is being studied. Pfizer's oral danuglipron was discontinued over tolerability and a liver signal, showing how hard oral GLP-1 drugs are to get right.
Do these drugs cause muscle loss?
GLP-1 based weight loss includes some loss of lean muscle. That is why muscle-focused agents like bimagrumab, which builds muscle while reducing fat, are being studied alongside GLP-1 drugs. This is educational information, not medical advice.
Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use.